RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma

Overview of attention for article published in Respiratory Research, May 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 7,834 followers.

RT @ATS_BSHSR: #RORγt #inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat #severe #asthm…

RT @ATS_BSHSR: #RORγt #inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat #severe #asthma https://t.co/Si2irGgHbz https://t.co/Le4K6MUge5

#RORγt #inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat #severe #asthma https://t.co/eWzDRHucdP https://t.co/tD3krawfeP

RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 ... https://t.co/d3xoQPwSHg

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.